The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
MicroRNA-135b Promotes Cancer Progression by Acting as a Downstream Effector of Oncogenic Pathways in Colon Cancer
Open accessAbstract
MicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether it represents a bystander event or actually drives tumor progression in vivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Self-citationFast and effective prediction of microRNA/target duplexes
REHMSMEIER, M., STEFFEN, P., HÖCHSMANN, M., & GIEGERICH, R. (2004) · RNA · doi:10.1261/rna.5248604 · Cited by 2,560
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Self-citationThe Interleukin-8 Pathway in Cancer
Waugh, D. J. J., & Wilson, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4843 · Cited by 2,103
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Mahon, P. C., Hirota, K., & Semenza, G. L. (2001) · Genes & Development · doi:10.1101/gad.924501 · Cited by 1,385
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×
“SRC is nonmembrane receptor tyrosine kinase (Yeatman 2004) and induces activation of several pathways.”
Cited by
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
m6A-dependent glycolysis enhances colorectal cancer progression
Shen, C., Xuan, B., Yan, T., Ma, Y., Xu, P., Tian, X., Zhang, X., Cao, Y., Ma, D., Zhu, X., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01190-w · Cited by 437
Mechanisms of PTEN loss in cancer: It’s all about diversity
Álvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.02.001 · Cited by 401
MicroRNA Detection Specificity: Recent Advances and Future Perspective
Ouyang, T., Liu, Z., Han, Z., & Ge, Q. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b05909 · Cited by 296
Integrin signalling regulates YAP/TAZ to control skin homeostasis
Elbediwy, A., Vincent-Mistiaen, Z. I., Spencer-Dene, B., Stone, R. K., Boeing, S., Wculek, S. K., Cordero, J., Tan, E. H., Ridgway, R., Brunton, V. G., et al. (2016) · Development · doi:10.1242/dev.133728 · Cited by 291
Self-citationMicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications
Strubberg, A. M., & Madison, B. B. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027441 · Cited by 147
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer
Cekaite, L., Eide, P. W., Lind, G. E., Skotheim, R. I., & Lothe, R. A. (2016) · Oncotarget · doi:10.18632/oncotarget.6390 · Cited by 84
Kwon, M.-S., Kim, Y., Lee, S., Namkung, J., Yun, T., Yi, S. G., Han, S., Kang, M., Kim, S. W., Jang, J.-Y., et al. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s9-s4 · Cited by 47
“Likewise, miR-135b was reported as a biomarker for PDAC [17], ovarian cancer, and colon cancer [18], in which it promotes proliferation, invasion, and metastasis [19], and miR-135b was similarly upregulated in our findings.”
ResultMiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells
Liang, H., Xu, Y., Zhang, Q., Yang, Y., Mou, Y., Gao, Y., Chen, R., Chen, C., & Dai, P. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2019.1569530 · Cited by 43
Metadata
- Authors
- Valeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J. R., Ueno, L., Grivennikov, S. I., Lovat, F., Paone, A., Cascione, L., Sumani, K. M., Veronese, A., Fabbri, M., Carasi, S., Alder, H., Lanza, G., Gafa’, R., Moyer, M. P., Ridgway, R. A., Cordero, J., Nuovo, G. J., Frankel, W. L., Rugge, M., Fassan, M., Groden, J., Vogt, P. K., Karin, M., Sansom, O. J., & Croce, C. M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 25
- Issue
- 4
- Pages
- 469-483
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2008802992
- Cited by
- 286
- References
- 48
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.